These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 26869247)

  • 1. Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.
    Fava M; Memisoglu A; Thase ME; Bodkin JA; Trivedi MH; de Somer M; Du Y; Leigh-Pemberton R; DiPetrillo L; Silverman B; Ehrich E
    Am J Psychiatry; 2016 May; 173(5):499-508. PubMed ID: 26869247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of opioid modulation in major depressive disorder.
    Ehrich E; Turncliff R; Du Y; Leigh-Pemberton R; Fernandez E; Jones R; Fava M
    Neuropsychopharmacology; 2015 May; 40(6):1448-55. PubMed ID: 25518754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.
    Fava M; Thase ME; Trivedi MH; Ehrich E; Martin WF; Memisoglu A; Nangia N; Stanford AD; Yu M; Pathak S
    Mol Psychiatry; 2020 Jul; 25(7):1580-1591. PubMed ID: 30374191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial.
    Pathak S; Vince B; Kelsh D; Shram MJ; Setnik B; Lu H; Nangia N; Stanford AD; Ehrich E
    J Clin Pharmacol; 2019 Feb; 59(2):206-217. PubMed ID: 30102427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder.
    Thase ME; Stanford AD; Memisoglu A; Martin W; Claxton A; Bodkin JA; Trivedi MH; Fava M; Yu M; Pathak S
    Neuropsychopharmacology; 2019 Dec; 44(13):2268-2276. PubMed ID: 31254971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder.
    Ragguett RM; Rong C; Rosenblat JD; Ho RC; McIntyre RS
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):475-482. PubMed ID: 29621905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3).
    Zajecka JM; Stanford AD; Memisoglu A; Martin WF; Pathak S
    Neuropsychiatr Dis Treat; 2019; 15():795-808. PubMed ID: 31040679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.
    Durgam S; Earley W; Guo H; Li D; Németh G; Laszlovszky I; Fava M; Montgomery SA
    J Clin Psychiatry; 2016 Mar; 77(3):371-8. PubMed ID: 27046309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
    Mischoulon D; Witte J; Levy M; Papakostas GI; Pet LR; Hsieh WH; Pencina MJ; Ward S; Pollack MH; Fava M
    J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic administration of buprenorphine in combination with samidorphan produces sustained effects in olfactory bulbectomised rats and Wistar-Kyoto rats.
    Burke NN; Li Y; Deaver DR; Finn DP; Roche M; Eyerman DJ; Sanchez C; Kelly JP
    J Psychopharmacol; 2019 Dec; 33(12):1620-1627. PubMed ID: 31512988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abuse Potential of Samidorphan: A Phase I, Oxycodone-, Pentazocine-, Naltrexone-, and Placebo-Controlled Study.
    Pathak S; Vince B; Kelsh D; Setnik B; Nangia N; DiPetrillo L; Puhl MD; Sun L; Stanford AD; Ehrich E
    J Clin Pharmacol; 2019 Feb; 59(2):218-228. PubMed ID: 30476361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.
    Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G
    Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants.
    Mischoulon D; Hylek L; Yeung AS; Clain AJ; Baer L; Cusin C; Ionescu DF; Alpert JE; Soskin DP; Fava M
    J Affect Disord; 2017 Jan; 208():6-14. PubMed ID: 27736689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
    Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
    J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
    Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
    Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW
    Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.